TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 18 to 65 years of age (inclusive)~* Diagnosed with bipolar I disorder, manic or mixed-type, per DSM-5 criteria~* Voluntary hospitalization for current manic episode~Exclusion Criteria:~* Patients with a DSM-5 diagnosis of a psychiatric disorder other than bipolar I disorder that was the primary focus of treatment within the previous six months~* Patients who are experiencing a first manic episode or meeting criteria for rapid cycling

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Iloperidone (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Signed informed consent~* Men and women aged between 40 and 85 years (inclusive)~* Body mass index \< 35 kg/m2~* Ability to communicate well with the investigator in the local language and to understand and comply with the requirements of the study~Exclusion criteria (any of the following):~* Known hypersensitivity to the study drug or any excipients of the drug formulation~* Treatment with another investigational drug within 3 weeks prior to screening~* History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug~* Severe renal failure (glomerula filtration rate \< 30 ml/min)~* Moderately or severe impaired left ventricular function (ejection fraction \< 40%)~* Moderately or severe impaired right ventricular function~* Systolic pulmonary pressure \> 45 mmHg~* Acute or recent (\<7 days) myocardial infarction~* Child bearing potential

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Heme arginate (high dose) (Type: EXPERIMENTAL): 24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
- Heme arginate (low dose) (Type: EXPERIMENTAL): 24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
- Placebo (Type: PLACEBO_COMPARATOR): 24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness Between Two Surgical Techniques for Reconstruction of Humeral Proximal Extremity Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with humeral proximal extremity fracture or fracture luxation in three or four fragments of Neer's classification.~* Patient 70 years older~* Signed informed consent.~Exclusion Criteria:~* Any condition to make worse the functional recovery or avoid the patient collaboration with the rehabilitation program ( cognitive disability, neurological pathology...)~  * Glenohumeral osteoarthritis~ * Inflammatory arthropathies~ * Previous cuff arthropatyy~ * High surgical or anesthesia risk~ * Any disease or condition that the investigator finds decisive for exclusion.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemiarthroplasty Global Fx(DePuy) (Type: ACTIVE_COMPARATOR): in this technique the prosthesis is implanted in similar approach to shoulder anatomy
- reverse arthroplasty Delta Xtent(DePuy) (Type: EXPERIMENTAL): In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or over~* Moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on Facial Wrinkle Scale as assessed by investigator's rating: 0= 'none', 1= 'mild', 2= 'moderate', 3= 'severe'~* Moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on Facial Wrinkle Scale as assessed by patient's assessment: 0= 'none', 1= 'mild', 2= 'moderate', 3= 'severe'~* Stable medical condition~Exclusion Criteria:~* Previous treatment with Botulinum toxin of any serotype in the glabellar area within the last 8 month~* Previous treatment with any facial aesthetic procedure (e.g. injection with biodegradable fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 month~* Previous insertion of permanent material in the glabellar area (regardless of the time between previous treatment and this study)~* Planned treatment with Botulinum toxin of any serotype in any other body region during the study period~* Any surgery in the glabellar area including surgical removal of the corrugator, procerus, or depressor supercilii muscles or a combination of these, or scars in the glabellar area and the surrounding areas (including eye brow)~* Any other planned facial aesthetic procedure during the trial period~* Inability to substantially lessen glabellar frown lines even by physically spreading them apart~* Marked facial asymmetry or ptosis of eyelid and/or eyebrow~* History of facial nerve palsy~* Any infection in the area of the injection sites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) (20 Units) (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Treatment in Sjogren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stimulated whole saliva secretion ≥ 0,15 ml/min~* Male or female \> 18 years~* Primary SS according to the revised European - U.S. criteria(22)~* Positive autoantibodies (IgM-Rf \> 10 and SS-A and/or SS-B)~* Parotid gland biopsy (paraffine material and fresh frozen tissue) with characteristic features of SS performed at time of inclusion (no longer than 12 months ago)~* Use of reliable method of contraception during the study~* Written informed consent~Exclusion Criteria:~* The presence of any other connective tissue disease~* Preceding treatment with anti-TNF or other monoclonal antibodies~* Use of prednisone, hydroxychloroquine less than 1 month ago~* Use of MTX, cyclophosphamide, cyclosporin, azathioprine and other DMARDS less than 0,5 year ago~* Serum creatine \> 2.8 mg/dl (250 micromol/l)~* ASAT or ALAT outside 1.5 x upper normal range of the laboratory~* Hb \< 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females~* Neutrophil granulocytes less than 0.5 x 109/l~* Platelet count less then 50 x 109/l~* Positive pregnancy test or breast-feeding~* History of alcohol or drug abuse~* Serious infections~* Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, chronic or latent infectious diseases or immune deficiency which places the patient at an unacceptable risk for participation in the study~* History of any malignancy with the exception of completely resected basal cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Urge or stress urinary incontinence at least twice a week on average for at least 3 months~Exclusion Criteria:~* History of previous acupuncture~* History of a neurologic problem such as Parkinson's disease or multiple sclerosis that could affect bladder function~* Current treatment with overactive bladder medications or medications that relax the bladder~* Urinary catheter~* Pregnancy~* Inability to empty the bladder effectively~* Inability to toilet independently~* Current treatment with steroid~* Interstitial cystitis~* Chronic pelvic pain~* Current treatment with warfarin

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acupuncture (Type: EXPERIMENTAL): Subjects will 12 acupuncture treatments over 6 weeks; treatment sessions occur twice a week. A total of 12 acupuncture needles will be inserted bilaterally at two leg points and four back points. Needles are manually inserted through a standard guide tube contained within a fitted sheath and the basal ring secured to the skin by double-sided tape. The needles remain in place for 25 minutes and are manually stimulated twice during each treatment.
- Sham acupuncture (Type: SHAM_COMPARATOR): Subjects will receive 12 sham acupuncture treatments (delivered twice a week) over 6 weeks. The sham needle is blunted needle whose shaft telescopes into the handle when tapped. While the needle appears to have been inserted, it does not actually penetrate the skin. It is held in place by the same standard guide tube used in the true acupuncture group. The acupuncture points and duration of treatment are the same as for the true acupuncture group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 25 to 32 6/7 weeks gestation~* Singleton or twin gestation~* Received 1st course of betamethasone prior to 30 weeks' gestation~* Began 1st course of betamethasone at least 14 days prior to randomization~* Risk of delivery in next 7 days due to either maternal or fetal complication (e.g. preterm labor, severe preeclampsia, IUGR, etc.)~* Intact membranes~Exclusion Criteria:~* Known major fetal anomalies (eg: anencephaly, renal agenesis etc...)~* High order multiple gestation (triplets or higher)~* Cervical dilation \> 5 cm~* Clinical chorioamnionitis prior to initiation of second course (two or more of the following; antepartum temperature \> 38ºC (100.4ºF), uterine tenderness, foul smelling vaginal discharge or amniotic fluid, maternal tachycardia (\>100beats/min), fetal tachycardia (\>160 beats/min), or white blood cell count \>20x109/L.define)~* Ruptured membranes prior to initiation of second course of betamethasone~* Already receiving corticosteroids for other conditions (e.g. Lupus, asthma)~* Maternal condition contraindicating the use of steroids (e.g. HIV, active Tuberculosis)~* Participation in conflicting study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 Test group (Type: ACTIVE_COMPARATOR): Receive 2nd Course = Study drug (betamethasone or dexamethasone)
- 2 - Control (Type: PLACEBO_COMPARATOR): Placebo group = received placebo course

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of BBT-I and Zopiclone for Chronic Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~meeting the criteria for chronic insomnia according ICSD-3 willingness to take part in the study and signed informed consent form~Exclusion Criteria:~1. unability to stop taking medications that have a proven impact on sleep at least one week before and during the study;~2. history of alcohol or drug abuse;~3. major depressive disorder or other severe mental disorder identified by a clinical assessment and medical history;~4. dementia;~5. pregnancy or lactation;~6. shift or night work;~7. medical problems that would be a direct cause of sleep complaints: moderate/severe sleep apnea, defined as an apnea-hypopnea index of ≥15 events per hour, periodic limb movement disorder defined as a periodic leg movement index ≥15 events per hour or restless legs syndrome;~8. other serious chronic conditions or exacerbation of chronic disorder preventing further participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- zopiclone first group (Type: EXPERIMENTAL): underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
- BBT-I first group (Type: EXPERIMENTAL): received two-week brief behavioral therapy followed by medication therapy (zopiclone).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Treatment of Plantar Fasciitis: Physical Training, Glucocorticoid Injections or a Combination Thereof.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pain at the medial attachment of fascia plantaris.~* First step pain in the morning~* Symptoms for at least 3 months.~* Age 20-65 years~* Ultrasound scanning at the first visit shows thickness of the fascia above 4 mm.~* Patient can read and understand danish~Exclusion Criteria:~* known arthritis, inflammatory bowl disease, psoriasis or clinical signs of any of these~* Leg ulcerations~* Longlasting oedema of the leg and foot~* Palpatory decreased puls in the foot~* Diabetes~* Reduced sensibility in the foot~* Infections in the foot~* Daily use of pain killers~* Pregnancy or planning to become pregnant~* Earlier operations on the foot, that is judged to complicate training~* Patient assessed not to be able to participate in the training for other reasons~* Glucocorticosteroid injection to the diseased plantar fascia within the last 6 months.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Training (Type: ACTIVE_COMPARATOR): strengthening and stretching exercises.
- Glucocorticosteroid injection (Type: ACTIVE_COMPARATOR): Injection of 40 mg methylprednisolone.
- Training and Glucocorticosteroid injections (Type: ACTIVE_COMPARATOR): A combination treatment of the two above.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The body weight should be less than or equal to 80 kilogram~* Participants who had a diagnosis of plaque-type psoriasis (scaly skin rash) greater than or equal to 6 months before Screening (participants with concurrent psoriatic arthritis \[joint pain\] may be enrolled)~* Participants who had plaque-type psoriasis covering greater than or equal to 10 percent of total body surface area, Psoriasis Area Severity Index (PASI) score greater than or equal to 12 at Screening and at the Baseline~* Participants who are candidates for systemic treatment of psoriasis~* Females of childbearing potential and all men must be using adequate birth control measures and agree to use these measures and should not become pregnant (carrying an unborn baby) or plan to become pregnant up to 6 months after receiving last infusion of study drug~Exclusion Criteria:~* Participants who have nonplaque forms of psoriasis ( for example, erythrodermic, guttate, or pustular), or have current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)~* Participants who are pregnant, nursing or planning to become pregnant within one year while enrolled in the study~* Participants who had previous treatment with infliximab~* Participants who have received agents targeted at reducing tumour necrosis factor or any biologic treatment within the previous 3 months~* Participants who have used any investigational drug within the previous 4 weeks or 5 times the half-life of the investigational agent, whichever is longer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: EXPERIMENTAL): 5 milligram per kilogram (mg/kg) infusion (a fluid or a medicine delivered into a vein by way of a needle) of infliximab administered intravenously (into a vein) at Week 0, 2 and 6 followed by maintenance regimen of 5 mg/kg infliximab at Week 14 and 22. Placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial infusion), matched to infliximab will be given at Week 10, 12 and 16. Total duration of treatment will be 26 weeks.
- Placebo (Type: EXPERIMENTAL): Placebo infusion, matched to infliximab will be given intravenously at Week 0, 2 and 6. At Week 10, 12 and 16, participants will receive 5 mg/kg infliximab intravenously. Placebo infusion will be again given at Week 14 and 22. Total duration of treatment will be 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients previously enrolled in C87059 (COSPAR I, NCT00349752)~Exclusion Criteria:~* Subject withdrawn or discontinued from C87059 (COSPAR I, NCT00349752) study under specific conditions~* Subject who received treatment other than study medication and other than medications permitted in C87059 (COSPAR I, NCT00349752)~* Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDP870 400 mg (Type: EXPERIMENTAL): Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete